ArticleEuropean heart journal. Acute cardiovascular care2026
Diagnostic validation of a novel high-sensitivity cardiac troponin T assay.
Article in European heart journal. Acute cardiovascular care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02355457 (Biomarkers in Acute Cardiac Care), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Biomarkers in Acute Cardiac Care
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
aimsHigh-sensitivity cardiac troponin (hs-cTn) assays are integral to evaluating suspected myocardial infarction (MI). A recently developed hs-cTnT assay requires diagnostic and prognostic evaluation. METHODS AND
resultsPatients presenting to the emergency department with suspected non-ST-elevation MI were prospectively evaluated. Discrimination was tested using the area under the curve (AUC). Diagnostic performance was assessed with previously derived cut-off concentrations and ESC 0/1 h algorithm. Head-to-head comparisons between the new and established assays were performed. Prognostic performance of hs-cTnT for 1-year mortality and major adverse cardiac events (MACE) was analysed using adjusted Cox regression. In 1415 patients, mean age 64 years and 64.2% male, MI was diagnosed in 12.1%. The novel TnT hs Gen 6 assay demonstrated excellent discrimination with an AUC on admission of 0.87 (95% CI: 0.84, 0.90) and 0.91 (95% CI: 0.89, 0.93) after 1 h. Using a 0 h cut-off <8 ng/L or <18 ng/L and Δ 0/1 h of <2 ng/L enabled rule-out in 54.3% (95% CI: 51.7%, 57.0%), with a NPV of 99.5% (95% CI: 98.7%, 99.9%); sensitivity was 97.7% (95% CI: 94.1%, 99.4%). For rule-in, a 0 h cut-off ≥112 ng/L or a Δ 0/1 h ≥ 10 ng/L yielded a PPV of 58.5% (95% CI: 51.9%, 64.9%) and specificity of 92.2% (95% CI: 90.6%, 93.6%) with rule-in of 16.5% (95% CI: 14.6%, 18.6%). Hs-cTnT was associated with 1-year mortality [hazard ratio (HR) 1.39 (95% CI: 1.28, 1.51)] and MACE [HR 1.22 (95% CI: 1.15, 1.29)].
conclusionThe novel hs-cTnT assay demonstrates high diagnostic accuracy to rule-out or diagnose MI and offers valuable prognostic information regarding 1-year mortality and MACE.Trial Registration: clinicaltrials.gov (NCT02355457).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.